title: An assessment by the Statin Diabetes Safety Task Force: 2014 update.
abstract: Statin therapy reduces the risk of myocardial infarction, stroke, and cardiovascular death by 25% to 30% in primary as well as secondary prevention patients. Thus, statins are the pharmacologic therapy of choice for the management of high blood cholesterol levels. Prompted by examination of clinical trial data suggesting a modest, but statistically significant, increase in the incidence of new-onset type 2 diabetes mellitus with statin use, the US Food and Drug Administration in 2012 added a statement to the labels of statin medications indicating that increases in glycated hemoglobin (HbA1C) and fasting glucose levels have been reported with statin use. This labeling change has raised questions among clinicians regarding the relative benefits and risks of statin use, both among patients with diabetes mellitus and among those with diabetes risk factors. This 2014 report from the Diabetes Subpanel of the National Lipid Association Expert Panel on Statin Safety reviews the published evidence relating statin use to the hazard for diabetes mellitus or worsening glycemia, examines potential mechanisms that may mediate the relationship between statin use and diabetes mellitus risk, and suggests future research efforts. Given the well-established benefits of statin therapy in the primary and secondary prevention of cardiovascular events among those with indications for treatment, no changes to clinical practice are recommended other than the measurement of HbA1C or fasting glucose in those deemed to also be at elevated diabetes risk after initiating statin therapy, and potentially before initiation in selected patients considered to be at elevated risk of developing diabetes. The panel advocates following recommendations from the American Diabetes Association, or other relevant guidelines if outside the United States, for screening and diagnosis as well as lifestyle modification for prevention or delay of diabetes mellitus in those with prediabetes or other risk factors.
authors.affiliation: Midwest Center for Metabolic & Cardiovascular Research and DePaul University, 6323 North Avondale Avenue, Suite 103, Chicago, IL 60631, USA. Electronic address: kmaki@mc-mcr.com.
authors.forename: Kevin C
authors.initials: KC
authors.lastname: Maki
authors.affiliation: Brigham and Women's Hospital and the Harvard Medical School, Boston, MA, USA.
authors.forename: Paul M
authors.initials: PM
authors.lastname: Ridker
authors.affiliation: Emory University School of Medicine, Atlanta, GA, USA.
authors.forename: W Virgil
authors.initials: WV
authors.lastname: Brown
authors.affiliation: The University of Texas Southwestern Medical Center, Dallas, TX, USA.
authors.forename: Scott M
authors.initials: SM
authors.lastname: Grundy
authors.affiliation: University of Glasgow, Glasgow, UK.
authors.forename: Naveed
authors.initials: N
authors.lastname: Sattar
authors.lastname: The Diabetes Subpanel of the National Lipid Association Expert Panel
mesh_terms: D001786:Blood Glucose / Q000032:analysis; D002318:Cardiovascular Diseases / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000209:etiology; D019317:Evidence-Based Medicine; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D016017:Odds Ratio; D012307:Risk Factors
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; C517652:hemoglobin A1c protein, human
keywords: Coronary heart disease; Lipid; National Lipid Association; Statin; Type 2 diabetes mellitus